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One of the challenges of radiation oncology in the era of personalized medicine is identification 
of biomarkers associated with individual radiosensitivity. The aim of research was to evaluate the 
possible clinical value of the associations between clinical, physical, and biological factors, and risk 
for development of acute radiotoxicity in patients with prostate cancer. The study involved forty four 
patients treated with three‑dimensional conformal radiotherapy. The concentrations of IL‑1β, IL‑2, 
IL‑6, IFN‑γ and TGF‑β1 were assessed before radiotherapy, after 5th, 15th and 25th radiotherapy 
fractions, at the end, and 1 month after the end of radiotherapy. Cytokine gene expression was 
determined in peripheral blood mononuclear cells. The univariate analysis of circulating cytokine levels 
during radiotherapy showed that increased serum concentrations of IL‑6 were significantly associated 
with higher grade of acute genitourinary toxicity. The multivariate analysis demonstrated that 
increased level of IL‑6 during the radiotherapy was significantly associated with higher grade of acute 
genitourinary toxicity across treatment. TGF-β expression levels significantly decreased during course 
of radiotherapy. Research indicates that changes in circulating cytokine levels might be important 
parameter of radiotoxicity in patients with prostate cancer. These findings suggest that future studies 
based on multi‑parameter examination are necessary for prediction of individual radiosensitivity.
In the era of personalized medicine, radiotherapy aims to permanently control a primary malignant tumor 
and regional lymph node metastases and thus avoiding normal tissue toxicity. Between 5% and 10% of cancer 
patients treated with radiotherapy develop severe side effects which may influence the response to radiotherapy 
and patients’ quality of  life1,2. Although efforts are constantly made to improve radiation therapy techniques, dose 
delivery, and optimization of treatment regimens further understanding of individual biological differences in 
patients is needed for development of personalized  radiotherapy3. There is a considerable interest in identifying 
biomarkers associated with patient’s individual radiosensitivity. According to the literature data Rubin et al. were 
among the pioneers in the field of radiation-induced toxicity in association with cytokine  level4. Cytokine expres-
sion is associated with radiation-related tissue damage and inflammation, and may serve as an indicator of cell 
and tissue toxicity during prostate cancer  radiotherapy5,6. Exposure to radiation initiates a programmed cellular 
response to promote tissue repair, which involves the induction and regulation of proinflammatory cytokines. 
Inflammation is thought to play a key role in the response of malignant tumors to radiotherapy. Previously 
published studies indicate an increase in circulating levels of proinflammatory cytokines during radiotherapy, 
such as IFN-ɣ, IL-6, TNF-α, and IL-47,8. Thus Stenmark et al. suggested that assessment of cytokines IL-8 and 
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TGF-β in combination with dose parameters may be useful for prediction of radiation–induced lung  toxicity2. 
Furthermore, it has been shown that there is a difference in the level of cytokines in patients with prostate cancer 
compared with patients with benign lesions and healthy individuals, as well as changes after radiotherapy and/or 
androgen  therapy3,9. Changes in the level of inflammatory biomarkers have also been shown to be positively cor-
related with fatigue symptoms, as well as with acute gastrointestinal and genitourinary  toxicity5,10. Radiotherapy 
in patients with prostate cancer causes inflammation leading to an increase in the circulating levels of IL-6, IL-8, 
TNF-α and TGF-β8. The study by Christensen et al.5 showed significant increases in serum levels of IFN-γ and 
IL-6 during radiotherapy in patients with prostate cancer. The elevated levels of IL-1 and IL-2 were associated 
with the risk of genitourinary and gastrointestinal radiotoxicity  development5.
Changes in levels of proinflammatory cytokines have been associated not only with radiation-induced toxic-
ity, but also with tumor response to radiotherapy. It has been found that an increase in IL-6 levels contributes to 
more aggressive tumor growth and resistance to treatment. The therapeutic modulation of IL-6 could increase 
the sensitivity of malignant tumors to  radiotherapy11. An increase in the percentage of regulatory T lymphocytes 
(Tregs) occurs in patients receiving radiotherapy, in various tumors, which is associated with poor therapeutic 
 response11,12. The radiotherapy response was inversely correlated with cytokine expression (TGF-β) and the 
level of Tregs in a mouse  model13. Likewise, surgery has been shown to lead to increased expression of cytokines 
similar to those found in the inflammatory response of gastrointestinal mucosa after  radiotherapy5,14–16. However, 
the complex role of proinflammatory cytokines in radiation therapy-related toxicity has not yet been completely 
elucidated.
The aim of the present study was to examine the potential clinical significance of the associations between 
clinical, physical, and multiple biological parameters from three different levels, which derived from the previous 
study which investigated association only between clinico-pathological and physical parameters and potential 
risk for development of acute  radiotoxicity17.
The longitudinal cytokine profiles in serum and gene expression levels in peripheral blood mononuclear 
cells for the prediction of individual sensitivity to radiotherapy in patients with prostate cancer in addition, the 
changes in the percentage of peripheral white blood cell subpopulations in these patients throughout the course 
of radiation therapy were assessed, as well. This integrated multi-level approach provides a better insight into 
biological effects of fractionated radiotherapy in the terms of more precise prediction of acute radiotoxicity. The 
examined six time points represent the resultant of cumulative effect of radiation during the therapy.
Results
Patients characteristics and radiation‑induced toxicity. The characteristics of the study cohort are 
shown in Table 1. Patient age ranged from 52 to 81 years, with a mean age of 69.2 years ± 7.1. Among examined 
patients 10 patients (21.3%) had diabetes mellitus type 2 (non-insulin dependent), 23 patients (48.9%) were 
active smokers during radiotherapy, 19 patients (40.4%) had chronic hypertension. Median Gleason score (GS) 
was 7 (min 6, max 9). Low, intermediate and high risk prostate cancer had 3 patients (8.3%), 14 patients (38.9%) 
and 19 patients (52.8%) respectively. For the whole group of patients, the initial level of prostate-specific antigen 
(PSA) in the blood before making clinical diagnosis ranged from 4.63 ng/mL to 57 ng/mL (median value was 
14.30 ng/mL). Definitive radiotherapy was performed in 21 patients (47.7%). Postoperative radiotherapy was 
performed in 23 patients (52.3%); in 6/23 patients radiotherapy was adjuvant, while in 17/23 patients radio-
therapy was salvage. Residual microscopic disease after radical prostatectomy was present in 9 out of 23 patients. 
After the 25th fraction of radiotherapy, grade 1 was the most common acute genitourinary radiotoxicity with a 
smaller fraction of patients showing grade 2 and 3 (Fig. 1). 
Changes in serum cytokine levels. To investigate whether changes in cytokine profiles correlate with 
radiation-induced acute genitourinary toxicity, the concentrations of IL-1β, IL-2, IL-6, IFN-γ and TGF-β1 were 
measured in serum of patients with prostate cancer undergoing radiotherapy before treatment initiation, after 
5th, 15th and 25th radiotherapy fractions, at the end of radiotherapy after last fraction, and 1 month after the 
end of radiotherapy.
The univariate analysis of circulating cytokine levels showed that the concentrations of IL-2, IFN-γ, and TGF-
β1 in sera of patients with prostate cancer tended to increase, but not statistically significant during course of 
radiotherapy (Table 2). Increased serum concentrations of IL-6 were significantly associated with higher grade of 
acute genitourinary toxicity (b = 0.018; p = 0.039). The trend for an association between increased concentrations 
of IL-2 and higher grade of acute genitourinary toxicity (b = 0.018; p = 0.081) was observed.
Multivariate multilevel ordinal regression analysis was used to determine whether changes in percentage 
of circulating lymphocytes and concentrations of IL-2 and IL-6 levels in sera of patients with prostate cancer 
treated with radiotherapy predicted changes in acute genitourinary toxicity over time. This analysis showed that 
decreased percentage of lymphocytes during time was significantly associated with higher grade of acute geni-
tourinary toxicity (b = − 0.013, p = 0.025, Table 3). Considering the changes in cytokine profiles, increased level 
of IL-6 during the course of radiotherapy was significantly associated with higher grade of acute genitourinary 
toxicity across treatment (b = 0.017, p = 0.046, Table 3). In addition, the increased level of IL-2 was associated with 
higher grade of acute genitourinary toxicity across treatment, although this association did not reach statistical 
significance (b = 0.020, p = 0.062, Table 3).
This finding for IL-2 might be attributed to the relatively small number of tested patients and/or to low tox-
icity grades during the course of radiotherapy observed in the group of analyzed patients. Thus seven patients 
had toxicity grades 2 and 3 after the 25th radiotherapy fraction, while 8 patients had toxicity grades 2 and 3 at 
the end of radiation therapy.
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Table 1.  Patient, clinical, tumor, and treatment characteristics. *Multilevel ordinal regression models with 
the degree of acute genitourinary toxicity as the dependent variable, adjusted for the observation and the type 
of treatment. Depending on the type of variables and the normality of distribution, data are shown as n (%), 





Mean age ± standard deviation 69.2 ± 7.1 0.020 0.152












Tumor volume in % of tissue sample, median, min, max 40 (12–80) 0.004 0.343
Gleason score, median, min, max 7 (6–9) − 0.016 0.857
Risk group
1 (low) 3 (8.3%)
0.131 0.2312 (intermediate) 14 (38.9%)
3 (high) 19 (52.8%)





Figure 1.  Changes in acute genitourinary toxicity grades in specific time points: PT-pre-treatment, 5F-after 
the 5th of radiotherapy, 15F- after the 15th fraction of radiotherapy, 25F-after the 25th fraction of radiotherapy, 
LF-at the last fraction of radiotherapy, and C-at the first control examination. Lines represent acute 
genitourinary toxicity grade changes in particular time points for each patient. Circle area is proportional to the 
number of patients. In the pre-treatment point it is 100%. On each time point, sum of circle area is 100%.
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The possible differences in temporal profiles of circulating cytokines and their association with acute genitou-
rinary toxicity were examined between patients treated with definitive radiotherapy who had intact prostate and 
patients treated with postoperative radiotherapy who had prostatectomy. According to the mixed effect model 
that analyses each time point for each individual, levels of IL-6 and IFN-γ were significantly higher in the sub-
group of patients treated with definitive radiotherapy than in the subgroup of patients treated with postoperative 
radiotherapy (p = 0.001 and p = 0.020, respectively, Supplementary Table 1).
The univariate analysis of the percentage of leukocyte or lymphocyte subpopulations in patients before 
radiotherapy, during the course of radiotherapy, and one month after end of radiotherapy is presented in Sup-
plementary Table 2.
Cytokine gene expression levels in peripheral blood mononuclear cells (PBMCs). Firstly, we 
compared pre-treatment cytokine gene expression levels with levels measured after the last fraction of radio-
therapy. TGF-β gene expression levels significantly decreased during radiotherapy (p = 0.043, Wilcoxon Signed 
Ranks Test, Fig. 2, Table 4) while IL-6 levels showed a non-significant trend towards lower (p = 0.075, Wilcoxon 
Signed Ranks Test, Table 4, Fig. 2).
Table 2.  Univariate analysis of cytokine levels in patients with prostate cancer during course of radiotherapy. 
*Multilevel ordinal regression models with the degree of acute genitourinary toxicity as the dependent variable, 
adjusted for the time point and the type of treatment. Depending on the type of variables and the normality of 










fraction After 1 month b p
Univariate analysis
IL-1β 1.2 (0.1–4.1) 1.0 (0.2–4.3) 1.3 (0.3–4.2) 1.3 (0.3–4.3) 1.2 (0.3–4.5) 1.2 (0.2–4.8) 0.018 0.712
IL-2 1.9 (0.2–27.9) 1.8 (0.2–17.8) 1.6 (0.3–32.2) 2.1 (0.3–26.1) 1.8 (0.2–36.4) 1.8 (0.2–18.8) 0.018 0.081
IL-6 2.6 (0.3–14.3) 2.5 (0.2–29.3) 2.4 (0.2–40.0) 2.6 (0.2–33.8) 1.9 (0–58.6) 2.5 (0.1–17.3) 0.018 0.039
IFN-γ 8.1 (2.2–96.3) 9.8 (1.3–52.1) 8.8 (1.3–78.0) 8.3 (1.8–90.5) 8.4 (1.3–107.7) 6.8 (1.9–52.9) 0.004 0.138
TGF-β1 42.7 (4.3–155.0) 43.1 (4.2–91.0) 46.3 (4.9–149.7) 44.6 (5.9–150.3) 45.6 (1.5–120.7) 41 (2.8–193.5) 0.001 0.516
Table 3.  Multivariate multilevel ordinal regression model of percentage of lymphocytes and concentrations 
of cytokines in patients with prostate cancer. *Multilevel ordinal regression model with the degree of acute 




Percentage of lymphocytes − 0.013 0.025
IL-2 0.020 0.062
IL-6 0.017 0.046
Figure 2.  Cytokine (TGF-β, INF-ɣ, and IL-6) gene expression time profile at pre-treatment time point and last 
fraction of radiotherapy-pairwise comparison.
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Secondly, we examined correlations between gene expression measured in PBMCs and protein levels meas-
ured in sera of matched patients, and detected no significant correlations in none of the compared groups 
(Table 5).
Correlations between lymphocyte subsets and gene expression levels of cytokines. Correla-
tion between immunophenotype (lymphocyte subsets) and gene expression levels of IL-6, IFN-γ, and TGF-β 
at pre-treatment time point and after the last fraction of radiotherapy showed a significant negative correla-
tion between IL-6 and  Foxp3+ (rho = − 0.580, p = 0.048, Table 6) or  CD4+CD25+Foxp3+ (rho = − 0.578, p = 0.049, 
Table 6) after the last fraction of radiotherapy. For the level of IFN-γ gene expression, a significant negative cor-
relation was found with the percentage of  Foxp3+CD4+CD25+ cells in PBL at pre-treatment time point and after 
the last fraction of radiotherapy (rho = 0.491, p = 0.053; rho = − 0.660, p = 0.002, respectively, Table 6). After the 
last fraction of radiotherapy the level of IFN-γ gene transcription shows significant negative correlation with the 
percentage of  Foxp3+ (rho = − 0.495, p = 0.027, Table 6) and  CD4+Foxp3+ (rho = − 0.685, p < 0.001, Table 6) cells 
in PBL. For the level of expression of TGF-β gene we found significant positive correlation with the mean fluo-
rescence intensity (MFI) of Foxp3 transcription factor in PBL after the last fraction of radiotherapy (rho = 0.463, 
p = 0.026, Table 6).
Table 4.  TGF-β, INF-ɣ, IL-6 gene expression profile at pre-treatment time point and after the last fraction of 
radiation therapy. N-number of patients. Wilcoxon’s test, pairwise comparison p values equal or less than 0.05 
were considered significant, and p values lower than 0.1 were considered as statistical trend.
Gene Time point N Median, minimum, maximum p value
TGF-β
Pre-treatment 18 22.4 (3.0–41.7)
0.043
Last fraction 18 14.5 (0.05–37.9)
INF-ɣ
Pre-treatment 13 2.0 (0.7–16.0)
0.507
Last fraction 13 4.6 (0.1–37.3)
IL-6
Pre-treatment 6 70.1 (12.8–359.8)
0.075
Last fraction 6 3.7 (1.0–48.5)
Table 5.  Correlations between gene and protein levels at pre-treatment point and after the last fraction 
of radiotherapy. N-number of patients. Spearman’s correlational test-p values equal or less than 0.05 were 
considered significant, and p values lower than 0.1 were considered as statistical trend.
Variable 1 Variable 2 N Time point Correlation coefficient p value
TGF-β protein TGF-β gene
22 Pre-treatment rho = 0.127 0.573
25 Last fraction rho = − 0.135 0.519
INF-ɣ protein INF-ɣ gene
14 Pre-treatment rho = 0.270 0.350
22 Last fraction rho = − 0.343 0.118
IL-6 protein IL-6 gene
9 Pre-treatment rho = − 0.400 0.286
14 Last fraction rho = − 0.150 0.610
Table 6.  Correlation of percentage of lymphocyte subset and gene expression level. *MFI-Mean Fluorescence 
Intensity. Correlation between percentage of lymphocyte subpopulation, MFI and relative expression levels of 
IL-6, INF-ɣ, and TGF-β. p values less than 0.05 were considered as statistically significant.
Percentage of lymphocyte subset Gene expression level N Time point Correlation coefficient p value
Foxp3 IL-6 9 Pre-treatment rho = − 0.317 0.406
Foxp3 IL-6 12 Last fraction rho = − 0.580 0.048
CD4+CD25+Foxp3 IL-6 9 Pre-treatment rho = − 0.326 0.391
CD4+CD25+Foxp3 IL-6 12 Last fraction rho = − 0.578 0.049
CD4+CD25+Foxp3 INF-ɣ 16 Pre-treatment rho = − 0.591 0.007
CD4+CD25+Foxp3 INF-ɣ 20 Last fraction rho = − 0.660 0.002
Foxp3 INF-ɣ 16 Pre-treatment rho = 0.181 0.502
Foxp3 INF-ɣ 20 Last fraction rho = − 0.495 0.027
CD4+Foxp3 INF-ɣ 16 Pre-treatment rho = − 0.069 0.799
CD4+Foxp3 INF-ɣ 20 Last fraction rho = − 0.685  < 0.001
Foxp3 MFI* TGF-β 21 Pre-treatment rho = 0.019 0.935
Foxp3 MFI TGF-β 23 Last fraction rho = 0.463 0.026
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Discussion
Many studies indicate that the assessment of temporal profiles of circulating cytokine levels in patients undergo-
ing radiotherapy could be a valuable approach for elucidation of their involvement in development of acute and 
late toxicity caused by radiological treatment as well as for monitoring radiotherapy response. The longitudinal 
examination of circulating cytokine profiles in our group of patients with prostate cancer treated with conven-
tionally fractionated conformal radiotherapy showed that increased levels of IL-2 and IL-6 during the treatment 
course were associated with higher grade of acute genitourinary toxicity. Our finding indicates that circulating 
IL-6 may be associated with acute radiation toxicity.
The results from a similar longitudinal study of cytokine expression patterns suggested that serum levels of 
IL-1, IL-2, IL-6 and IFN-γ in patients with prostate cancer during intensity-modulated radiotherapy may be 
predictive for acute radiation-induced normal tissue  toxicity5. The changes in IL-2, IL-6 and IFN-γ over baseline 
were associated with increased gastrointestinal toxicity, while the changes in IL-1 and IFN-γ were associated 
with increased genitourinary  toxicity5. Although Christensen et al.5 found that circulating IL-6 was significantly 
elevated in patients with prostate cancer during radiotherapy, this increase of IL-6 level was not associated with 
acute genitourinary toxicity as it was observed in our study. Differences between those two studies might be the 
consequence of the fact that they have used IMRT, while we used 3D conformal radiotherapy, and because of 
individual differences among patients and observed time points. The results of prospective, longitudinal, phase 
II study showed that the serum levels of IL-6 tended to increase in patients with early stage prostate cancer 
during external beam  radiotherapy18. The observed differences in temporal patterns of cytokine expression and 
their relationship with acute toxicity in prostate cancer patients between different studies might be attributed 
to differences in radiotherapy modalities, dose and volume of the irradiated tissue, in addition to differences 
in individual patient’s response to radiotherapy. It has been suggested that various biological factors may affect 
radiation – induced inflammatory response and cytokine signatures, such as genetic and epigenetic factors, 
pathohistological and molecular characteristics of the malignant tumors, tumor microenvironment, patient’s 
general health condition in addition to radiation therapy dose and volume of the irradiated  tissue6,19,20. The 
cytokine IL-6 has been suggested as one of the most promising immunological markers that might be useful as 
additional factor for prediction of radiation-induced normal tissue  toxicity6,19,21, not only for prostate cancer, 
but also for other types of cancer. The research conducted by Siva et al.22 reported that the early alterations in 
plasma IL-6 concentrations had been related with higher grade lung toxicity in patients with non-small cell lung 
cancer treated with  radiotherapy22.
Evaluation of possible prostate-cancer specific cytokine signatures in our group of patients showed signifi-
cantly higher circulating levels of IL-6 and IFN-γ in subgroup of patients receiving definitive radiotherapy in 
comparison with subgroup of patients receiving postoperative radiotherapy, which might be the consequence 
of higher maximal dose (72 Gy definitive radiotherapy group, and 66 Gy dose for postoperative and salvage 
radiotherapy group), or the consequences of irradiated volumes, that differed among groups, or the result of 
interplay between various factors such as presence of prostate and irradiation.
This finding for IL-6 was expected since prostate cancer cells produce this pro-inflammatory cytokine involved 
in the inflammatory response to ionizing  radiation6,23. Tazaki et al.24 reported increased serum level of IFN-γ in 
patients with prostate  carcinoma24.
There is growing evidence that PBMCs are capable of releasing a biologically active  secretome25. It is a well-
known fact that the first lines of response to irradiation are cells of the immune system. Helper T lymphocytes 
 CD4+ T (Th) are extremely radiosensitive cell  population26. TGF-β regulates differentiation, immune response, 
and development of T cells and regulates formation of  Foxp3+ regulatory T and inflammatory T helper Th17 
 cells27.
In our research we have measured systemic cytokine gene expression profile in PBMC of the same patients 
that we measured sera levels. We did not find any significant correlation between TGF-β, INF-ɣ, and IL-6 gene-
protein levels from PBMCs and serum, respectively, probably due to a great complexity of molecular interactions 
of the cytokine secretome, including miRNA-mRNA interaction and two models-translational repression, RNA 
decay, or combined  effect28. Secondly, different cell subtypes such as endothelial cells, fibroblasts, etc. produce 
cytokines, so sera contain the complete cytokine secretome, unlike PBMCs.
According to our results, TGF-β and IL-6 levels in PBMCs decreased during the course of radiotherapy 
compared with baseline. Stenmark et al.2 showed radiation-induced increase of plasma levels of TGF-β and IL-6 
in lung cancer patients. Bouquet et al. have shown that TGF-β inhibition increases radiosensitivity of breast 
tumor  cells29. IL-6 level decrease is associated with increased sensitivity to  radiotherapy29 and with radiotoxicity. 
Lowering of TGF-β might be associated with increased radiosensitivity after the last fraction of radiotherapy.
Lymphocytes are generally regarded as radiosensitive and indeed the overall percentage of circulating lym-
phocytes in peripheral blood decreased during the course of radiotherapy. However, in patients with prostate 
cancer undergoing radiotherapy before treatment initiation, there was no significant effect on the percentage of 
 CD4+ and  CD8+ T lymphocytes, Tregs, NK or NKT cell subsets at the end of radiotherapy. Numerous studies have 
shown that Tregs contribute to development and progression of various malignant tumors. However, it has been 
shown that radiotherapy inhibits apoptosis of Tregs and thereby increases the production of Tregs and also the 
recruitment of Tregs to local tumor  microenvironment30. IL-6 is a pleiotropic cytokine involved in the regulation 
of the immune response, inflammation and hematopoeisis. IL-6 can be detected in the serum, although baseline 
levels are low in the absence of inflammation. IL-6 is also involved in regulation of the balance between two T 
cell subsets: Tregs and Th17, which have opposing functions in the control of  inflammation31. In this study there 
is a negative correlation between the level of IL-6 gene expression and the percentage of Tregs in PB in patients 
with prostate cancer which is the most prominent after last fraction of radiotherapy. These findings are in agree-
ment with well-established role of IL-6 in downregulation of the expression of Foxp3 transcription factor that 
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represents the lineage specific marker of Tregs and therefore IL-6 inhibits differentiation of  Tregs32,33. Regulatory 
T cells (Tregs) have the role to suppress immune response maintaining homeostasis and self-tolerance. There-
fore, by various mechanisms these cells suppress the immunity to infection and tumors. In this study we found 
the negative correlation between the percentage of Tregs and IFN-γ gene level, especially after last fraction of 
radiotherapy. It has been shown that Tregs selectively reduce the transcriptional level of IFN-γ without blocking 
the expression of its Tbet transcription factor. In addition, Treg-mediated blockade of IFN-γ is dependent on 
Treg-derived IL-10 immunosuppressive  cytokine34. Tregs are the most important producers of TGF-β. In this 
study there is significant positive correlation between the MFI of Foxp3 transcription factor in PBL and TGF-
β gene transcription after the last fraction of radiotherapy. This cytokine released after radiotherapy displays 
protumorogenic and prometastatic role in some  tumors35.
Conclusion
Our study shows that changes in circulating cytokine levels during the course of radiation therapy rather than 
absolute levels might be important parameters of radiotoxicity. The levels of IL-6 significantly changes during 
radiotherapy, and is associated with the time of measurement and with the presence of prostate and radio-
therapy type, IL-2 levels change during the course of radiotherapy independently of the presence of prostate, 
while changes in INF-ɣ depend on the presence of prostate and radiotherapy type. Our findings point out that 
future studies should be designed with more levels of patients subgrouping and stratification according to type 
of radiation treatment and radiation schedules in order to lower the influence of physical and biological factors. 
The future of test development for prediction of individual radiosensitivity might be based on determination of 
cytokine levels changes at specific time points during course of radiotherapy which is only a part of the complex 
multifactorial puzzle influencing the radiotoxicity.
Methods
Patients. Forty four patients who had a histologically confirmed localized or locally advanced prostate 
cancer (PC) were treated with 3D conformal radiotherapy (3DCRT) at the Institute of Oncology and Radiol-
ogy of Serbia from January 2016 to August 2017 with definitive (in 21 patients) or postoperative (23 patients) 
radiotherapy without previous hormonal therapy. All patients had Karnofsky index (KI) ≥ 80. The details of the 
study were explained to the patients and informed consent forms were signed by the participants. The study 
protocol was approved by the Ethics Committee of the Institute of Oncology and Radiology of Serbia (approval 
No3348/1–01). The study was carried out according to the principles of the Declaration of Helsinki.
Acute radiotoxicity was evaluated according to RTOG/EORTC (Acute Radiation Morbidity Scoring Criteria) 
modified by  Peeters36, as well in our previous  study17. According to Peeters and coworkers, side-effects occur-
ring within 120 days from the start of radiotherapy were considered as acute radiation morbidity. Late toxicity 
was scored from 120 days after the start of treatment any times. All clinical data, and blood samples, were pro-
spectively collected. Serum and PBMC samples were obtained from all patients who were to participate in the 
studies. The radiation oncologist recorded baseline symptoms and acute symptoms during radiotherapy and at 
first control (30 days after the end of radiotherapy). Exclusion criteria were as follows: chronic infective diseases, 
neoadjuvant or concomitant hormonal therapy, the presence of enlarged lymph nodes (N1 stage) detected by 
imaging methods, the presence of distant metastasis (M1 stage) detected by imaging techniques, Karnofsky 
index < 80, and previous pelvic irradiation.
Treatment regimen. 3DCRT was performed according to the protocol of the Institute of Oncology and 
Radiology of Serbia, partly described in our previous published  article17. Patients treated with definitive radio-
therapy received irradiation to different volumes according to the estimated risk of seminal vesicle (SV) involve-
ment, and lymph node involvement according to the Roach formula. Thus patients were allocated to one of the 
following three groups: (1) prostate-only group (P) if the risk for SV involvement was < 15%; (2) prostate and 
seminal vesicle group (P + SV), if the risk SV involvement was ≥ 15%; (3) whole pelvic radiotherapy (WPRT) 
group if the risk for lymph node involvement was ≥ 15%. Clinical target volume (CTV) and Planning target 
volume (PTV) were used as standardized nomenclature according to International Commission on Radiation 
Units and Measurements recommendations ICRU 50 and ICRU  6237,38. CTV included the whole prostate. CTV1 
included whole prostate with entire seminal vesicle. CTV lnn encompassed the lymph node below of bifurcation 
of a. iliaca communis. The planning target volumes (PTV and PTV1) included 10 mm margins around the CTV 
or CTV1 and CTV lnn except the posterior margin which was reduced to 8 mm. PTV2 and PTV3 included 
margins around CTV. Margins for PTV2 and PTV3 were reduced to 5 mm except the posterior margin which 
was further reduced to 0 mm.
Patients were irradiated with a conventional fractionation regime: 2 Gy daily, 5 days weekly.
The prescribed dose to the ICRU reference volume to cover PTV, in the P only group, was 72 Gy. In the second 
group the prescribed dose to cover PTV1 was 66 Gy and to cover PTV2 was 6 Gy. In third group prescribed dose 
were 44 Gy for PTV1, 22 Gy for PTV2 and 6 Gy for PTV3.
All patients treated with definitive radiotherapy received 72 Gy in 36 fractions.
Patients who were irradiated after radical prostatectomy had one or two dose volume groups. If pN status was 
N0 they received 66 Gy to the PTV (prostate bed + /-SV). If pN status was Nx or N1 they received 44 Gy to PTV1 
(cover pelvic lymph node and the prostate + /- SV bed) followed by 22 Gy to PTV2 (cover the prostate + /- SV 
bed). The SV bed was irradiated in patients with stage pT3b in the pathological report. All patients treated with 
postoperative or salvage radiotherapy received 66 Gy in 33 fractions.
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Determination of serum cytokine concentrations. The concentrations of IL-1β, IL-2, IL-6, IFN-γ 
and TGF-β1 in the sera of patients with prostate cancer were determined by commercial uncoated ELISA kits, 
according to manufacturer instructions (Invitrogen). The concentrations of cytokines were determined before 
radiotherapy, after 5th, 15th and 25th radiotherapy fractions, at the end of radiotherapy, and 1 month after the 
end of radiotherapy.
In brief, ELISA plates were coated with appropriate capture antibodies in coating buffer and incubated over-
night at 4 °C. The plates were washed and blocked with ELISA/ELISASPOT Diluent. After 1 h incubation the 
plates were washed and serum samples and standards were added to the wells. The plates were incubated over-
night at 4 °C for maximum sensitivity. After washing and aspiration, detection antibody solution was added to 
each well and plates were incubated for 1 h. Subsequently, the plates were washed and aspirated; avidin-HRP 
solution was added to the wells and incubated for 30 min. The plates were washed and (3,3′,5,5′-Tetramethylb-
enzidine) TMB solution was added to each well. The plates were incubated for 15 min at room temperature and 
the enzymatic reaction was terminated by adding stop solution. The absorbance was measured at a wavelength 
of 450 nm using Multiskan EX Thermo Labsystems plate reader. The serum samples were run in duplicate.
Cytokine gene expression analysis. Cytokine gene expression in peripheral blood mononuclear cells 
(PBMCs) was examined at two time points: (1) at baseline (before radiotherapy) and (2) after the last fraction 
of radiotherapy. Total RNA from PBMCs was extracted with TRI Reagent (Sigma Aldrich). RNA was quanti-
fied on Biospec-nano (Shimadzu Biotech, Japan). Reverse transcription reaction preceded real-time quantitative 
PCR (RT-qPCR) reaction, performed with High Capacity cDNA Reverse Transcription Kit (Applied Biosystems 
by Thermo Fisher Scientific, Vilnius, Lithuania). The cDNA amplification reaction included primers against 
INF-ɣ (Hs00989291_m1), IL-6 (Hs00174131_m1), and TGF-β (Hs00998133_m1) and Taqman2xUniversal PCR 
Master Mix, No Amperase UNG (Applied Biosystems, by Life Technologies, Warrington, UK). As endogenous 
control for data normalization, GAPDH (Hs02758991_g1) was used. Gene expression is presented in relative 
quantity (RQ) units using the comparative 2-ΔΔCt method on 7500 System SDS software (Applied Biosystems, 
Foster City, California, USA).
Flow cytometry. Direct immunofluorescence staining was performed on peripheral blood (PB) using spe-
cific monoclonal antibodies (mAbs) and isotype-matched mAbs. Briefly, 50 μL of PB was incubated with 2.5 μL 
of appropriate monoclonal antibody combination for 15 min at room temperature in the dark. According to 
manufacturer’s protocol (Becton Dickinson), samples were lysed with 1X FACS Lysing Solution (Becton Dickin-
son), washed twice with phosphate-buffered saline (PBS) and fixed with 1% paraformaldehyde solution prior to 
acquisition. Surface marker expression was quantified on FACS Calibur flow cytometer (Becton Dickinson, San 
Jose, USA). A total of 10 000—50 000 gated events verified as peripheral blood lymphocytes (PBL), according 
to both, their physical characteristics forward scatter characteristics (FSC) and side scatter characteristics (SSC) 
were collected per sample and analyzed using CellQUEST software.
Within the lymphocyte gate we analyzed the percentage of CD3 (FITC-conjugated, Becton Dickinson R&D) 
and CD4 (PerCP-conjugated, Becton Dickinson) positive helper T cells and CD8 (PE-conjugated, Becton Dickin-
son), CD3 negative CD16CD56 positive (CD3-FITC-conjugated, CD16CD56-PE-conjugated Becton Dickinson) 
cells NK cells.
Intracellular staining for Foxp3 transcription factor. Staining for Foxp3 transcription factor was per-
formed using PE Mouse anti-human FoxP3 antibody and Human FoxP3 Buffer Set (BD Pharmingen). Accord-
ing to the manufacturer’s protocol. Briefly, the samples were stained for CD25 and CD4 cell surface markers, and 
washed with Stain Buffer (FBS) (BD Pharmingen). The cells were fixed with Human FoxP3 Buffer A and permea-
bilized with Human FoxP3 Buffer C. After resuspension in 100 μL of FBS Stain Buffer the cells were incubated 
with 5 µL of antibody specific for FoxP3 for 30 min at room temperature, protected from light and washed with 
Stain Buffer prior to flow cytometry analysis.
Statistical analysis. Depending on the type of variables and distribution normality, data are presented as 
n (%), average ± SD or median (min–max). The relationship between variables was estimated using the Spear-
man coefficient of correlation. For the modeling of the relationship of the ordinal dependent variable (acute 
genitourinary toxicity) in repeated measurements with potential predictors, a multilevel ordinal regression was 
used. Changes in outcomes were examined across the study time course with a linear mixed effects modeling 
approach implemented in the lme4 package for the R statistical computing environment (R Core Team, Vienna, 
Austria,2019)18. Toxicity predictors from univariate analyzes which were statistically significant were included in 
the multivariate multilevel ordinal regression model. The level of statistical significance was set at 0.05.
The correlation between percentage of specific lymphocyte subsets and gene expression levels at pre-treatment 
time point and at the last fraction was analyzed using Spearman’s correlation.
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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